Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Completed · Phase 1
Conditions studied: Sickle Cell Disease
In brief
Sickle cell disease (SCD) is an inherited blood disorder that causes the red blood cells to change their shape from a round shape to a half-moon/crescent or sickled shape. People who have SCD have a different type of protein that carries oxygen in their blood (hemoglobin) then people without SCD. This different type of hemoglobin makes the red blood cells change into a crescent shape under certain conditions. Sickle-shaped cells are a problem because they often get stuck in blood vessels blocking the flow of blood, and cause inflammation and injury to the important areas in the body. Lexiscan is drug that may prevent this inflammation and injury caused by the sickle shaped cells. This drug is approved by the FDA to be used as a fast infusion during a heart stress test in people who are unable to exercise enough to put stress on their heart by making it beat faster. Lexiscan has never been studied in patients with SCD and has never been given as a long infusion.
Key facts
- Study ID
- NCT01085201
- Run by
- Dana-Farber Cancer Institute
- People needed
- 39
- Starts
- 2010-04-01
- Expected to finish
- 2013-03-01
- Last updated by the study team
- 2014-03-07
Who can join
Age: 10 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Howard University Hospital — Washington D.C., District of Columbia, United States
- Johns Hopkins University — Baltimore, Maryland, United States
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- Childrens Hospital Boston — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Washington University — St Louis, Missouri, United States
- Blood Center of Wisconsin — Milwaukee, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.